Plain-English translation of NCT06964113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a treatment study testing filgotinib, a daily oral medication, in people with moderate to severe ulcerative colitis who haven't responded well to other treatments or couldn't tolerate them. Researchers want to see whether the medication can help reduce inflammation and bring patients into remission (where symptoms go away or nearly disappear). The study is enrolling 94 Korean adults and will track their progress over 10 to 22 weeks.
Ulcerative colitis is a chronic bowel disease that causes painful inflammation and isn't always controlled by existing treatments. This trial exists to see whether this new medication could offer another effective option for people whose disease hasn't been controlled with conventional or biologic therapies.
If you join, you will take the medication once daily by mouth for up to 22 weeks. You'll visit the clinic at specific timepoints so doctors can check how you're responding—including blood tests and possibly repeat endoscopy to confirm whether remission has been achieved. The study is open-label, meaning both you and your doctor will know you're receiving the medication (not a placebo).
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
South Korea